{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:46:13Z","timestamp":1791297973316,"version":"4.1.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>The natural history of malignant pheochromocytoma or paragangliomas (MPP) remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The primary aim of this study was to define progression-free survival at 1 year in therapy-naive patients with MPP. Secondary objectives were to characterize MPP and to look for prognostic parameters for progression at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting:<\/jats:title>\n                    <jats:p>The files of MPP followed up between January 2001 and January 2011 in two French Endocrine Networks were retrospectively reviewed. Therapy-naive patients were enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures:<\/jats:title>\n                    <jats:p>The main outcome was progression-free survival at 1 year in therapy-naive MPP patients according to Response Evaluation Criteria In Solid Tumors 1.1 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety files (46 men, 44 women, mean age of 47.5 \u00b1 15 years) were reviewed on site by one investigator. MPP characteristics were as follows: presence of an adrenal primary, a mitotic count exceeding 5 per high power field, hypertension, inherited disease, and presence of bone metastases in 50%, 22%, 60%, 49%, and 56% patients, respectively. Fifty-seven of the 90 patients with MPP (63%) were classified as therapy-naive. The median follow-up of these 57 patients was 2.4 years (range, 0.4\u20135.7). At 1 year, progression-free survival was 46% (CI 95: 33\u201359). Twenty-six of 30 (87%) patients with progression at 1 year had exhibited progressive disease at the first imaging workup performed after a median of 5.7 months. No prognostic parameter was identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Half of the therapy-naive patients with MPP achieved stable disease at 1 year. In symptom-free patients with MPP, a wait-and-see antitumor policy seems appropriate as first line. Modality for a prospective follow-up is proposed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2013-1907","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T10:28:48Z","timestamp":1374748128000},"page":"4006-4012","source":"Crossref","is-referenced-by-count":107,"title":["One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma"],"prefix":"10.1210","volume":"98","author":[{"given":"S\u00e9gol\u00e8ne","family":"Hescot","sequence":"first","affiliation":[{"name":"Institut Gustave Roussy (S.H., S.L., C.C., M.S., E.B.), Service de M\u00e9decine Nucl\u00e9aire et de Canc\u00e9rologie Endocrinienne, and Universit\u00e9 Paris-Sud, Villejuif F-94805, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy (S.H., S.L., C.C., M.S., E.B.), Service de M\u00e9decine Nucl\u00e9aire et de Canc\u00e9rologie Endocrinienne, and Universit\u00e9 Paris-Sud, Villejuif F-94805, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (L.A., P.-F.P.), H\u00f4pital Europ\u00e9en Georges Pompidou, Service d'Hypertension Art\u00e9rielle, Paris F-75015, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Vezzosi","sequence":"additional","affiliation":[{"name":"CHU Larrey (D.V.), Service d'Endocrinologie, Maladies M\u00e9taboliques et Nutrition, Toulouse F-31059, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy (I.B.), Biostatistic and Epidemiology Service and Universit\u00e9 Paris-Sud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bournaud-Salinas","sequence":"additional","affiliation":[{"name":"Groupement Hospitalier Lyon-Est (C.B.S., C.d.l.F., S.G., F.B.-C.), F\u00e9d\u00e9ration d'Endocrinologie et Centre de M\u00e9decine Nucl\u00e9aire, Bron F-69677, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardiere","sequence":"additional","affiliation":[{"name":"Groupement Hospitalier Lyon-Est (C.B.S., C.d.l.F., S.G., F.B.-C.), F\u00e9d\u00e9ration d'Endocrinologie et Centre de M\u00e9decine Nucl\u00e9aire, Bron F-69677, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Lib\u00e9","sequence":"additional","affiliation":[{"name":"Coordinator of the COrtico-MEdullo Tumeurs Endocrines group (R.L.), Lille F-59037, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[{"name":"CHRU de Lille (C.D.C., J.-L.W.), Clinique Endocrinologique Marc-Linquette, Lille F-59037, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Niccoli","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille (P.N.), CHU la Timone, Service d'Endocrinologie, Marseille F-13385, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"CHU Bordeaux (A.T.), Service d'Endocrinologie, Diab\u00e9tologie et Maladies M\u00e9taboliques, Pessac F-33600, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Raingeard","sequence":"additional","affiliation":[{"name":"H\u00f4pital Lapeyronie (I.R.), Maladies Endocriniennes, Montpellier F-34285, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Chougnet","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy (S.H., S.L., C.C., M.S., E.B.), Service de M\u00e9decine Nucl\u00e9aire et de Canc\u00e9rologie Endocrinienne, and Universit\u00e9 Paris-Sud, Villejuif F-94805, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Giraud","sequence":"additional","affiliation":[{"name":"Groupement Hospitalier Lyon-Est (C.B.S., C.d.l.F., S.G., F.B.-C.), F\u00e9d\u00e9ration d'Endocrinologie et Centre de M\u00e9decine Nucl\u00e9aire, Bron F-69677, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (A.-P.G.-R.), H\u00f4pital Europ\u00e9en Georges Pompidou, Service de G\u00e9n\u00e9tique, Paris F-75015, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Young","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (J.Y.), H\u00f4pital de Bic\u00eatre, Service d'Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bic\u00eatre F-94275, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Borson-Chazot","sequence":"additional","affiliation":[{"name":"Groupement Hospitalier Lyon-Est (C.B.S., C.d.l.F., S.G., F.B.-C.), F\u00e9d\u00e9ration d'Endocrinologie et Centre de M\u00e9decine Nucl\u00e9aire, Bron F-69677, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (J.B., X.B.), H\u00f4pital Cochin, Service d'Endocrinologie, Paris F-75014, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Wemeau","sequence":"additional","affiliation":[{"name":"CHRU de Lille (C.D.C., J.-L.W.), Clinique Endocrinologique Marc-Linquette, Lille F-59037, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bertagna","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (J.B., X.B.), H\u00f4pital Cochin, Service d'Endocrinologie, Paris F-75014, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Francois","family":"Plouin","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (L.A., P.-F.P.), H\u00f4pital Europ\u00e9en Georges Pompidou, Service d'Hypertension Art\u00e9rielle, Paris F-75015, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy (S.H., S.L., C.C., M.S., E.B.), Service de M\u00e9decine Nucl\u00e9aire et de Canc\u00e9rologie Endocrinienne, and Universit\u00e9 Paris-Sud, Villejuif F-94805, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy (S.H., S.L., C.C., M.S., E.B.), Service de M\u00e9decine Nucl\u00e9aire et de Canc\u00e9rologie Endocrinienne, and Universit\u00e9 Paris-Sud, Villejuif F-94805, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071620135956700_B1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"2020071620135956700_B2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma","volume":"229","author":"Goldstein","year":"1999","journal-title":"Ann Surg"},{"key":"2020071620135956700_B3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"2020071620135956700_B4","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J Clin Oncol"},{"key":"2020071620135956700_B5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"2020071620135956700_B6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res"},{"key":"2020071620135956700_B7","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B8","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1210\/jc.2008-2697","article-title":"Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy","volume":"94","author":"Nomura","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"2020071620135956700_B10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"2020071620135956700_B11","first-page":"100","article-title":"(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2020071620135956700_B12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020071620135956700_B13","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B14","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"key":"2020071620135956700_B15","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1677\/ERC-08-0049","article-title":"Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma","volume":"15","author":"Timmers","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2020071620135956700_B19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020071620135956700_B20","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"2020071620135956700_B21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/EJE-11-0497","article-title":"The genetics of phaeochromocytoma: using clinical features to guide genetic testing","volume":"166","author":"Jafri","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2020071620135956700_B22","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020071620135956700_B23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2020071620135956700_B24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2020071620135956700_B25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","author":"Durante","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2020071620135956700_B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/ERC-09-0319","article-title":"Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas","volume":"18","author":"Hentic","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"2020071620135956700_B27","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620135956700_B28","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"key":"2020071620135956700_B29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"key":"2020071620135956700_B30","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"2020071620135956700_B31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.mnm.0000189780.54658.e8","article-title":"Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites","volume":"27","author":"Mamede","year":"2006","journal-title":"Nucl Med Commun"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/10\/4006\/10781226\/jcem4006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/10\/4006\/10781226\/jcem4006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:08:40Z","timestamp":1594948120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/10\/4006\/2834116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-1907","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}